Mydecine Innovations Group (DB:0NF0) - Hisse Senedi Fiyatı, Haberler ve Analizler

0NF0 Stoklara Genel Bakış

Bir biyoteknoloji şirketi olan Mydecine Innovations Group Inc. ruh sağlığı sorunlarını tedavi etmek için psilosibin ürünlerinin araştırılması, geliştirilmesi ve ticarileştirilmesiyle ilgilenmektedir. Daha fazla detay

0NF0 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 8.7% oranında arttı

Risk Analizi

Geliri 1 milyon ABD dolarından az ( CA$0 )

Anlamlı bir piyasa değeri yok ( €333K )

1 yıldan az nakit akışı var

Negatif hissedar öz sermayesi

+ 2 daha fazla risk

Mydecine Innovations Group Inc. Rakipler

Biofrontera

XTRA:B8FK

€15.4m

SynBiotic

DUSE:SBX

€27.9m

MPH Health Care

DB:93M1

€103.6m

Redx Pharma

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Mydecine Innovations Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.003
52 Haftanın En Yüksek Seviyesi	US$0.076
52 Haftanın En Düşük Seviyesi	US$0.0005
Beta	2.77
11 Aylık Değişim	0%
3 Aylık Değişim	-80.00%
1 Yıllık Değişim	-96.00%
33 Yıllık Değişim	-99.95%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0NF0	DE Pharmaceuticals	DE Pazar
7D	0%	1.2%	1.3%
1Y	-96.0%	-19.7%	7.9%

Getiri vs. Endüstri: 0NF0 geçen yıl % -19.7 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 0NF0 geçen yıl % 7.9 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0NF0's price volatile compared to industry and market?
0NF0 volatility
0NF0 Average Weekly Movement	120.2%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 0NF0 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 0NF0 'nin haftalık oynaklığı son bir yılda 633% dan 120% a düştü, ancak hâlâ German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	3	Josh Bartch	www.mydecine.com

Bir biyoteknoloji şirketi olan Mydecine Innovations Group Inc. ruh sağlığı koşullarını tedavi etmek için psilosibin ürünlerinin araştırılması, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Şirket öncelikle nikotin bağımlılığı ve travma sonrası stres bozukluğu tedavisine odaklanmaktadır. Öncü ürün ilaç adayları arasında MYCO-005 bulunmaktadır.

Mydecine Innovations Group Inc. Temel Bilgiler Özeti

Mydecine Innovations Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0NF0 temel i̇stati̇sti̇kler
Piyasa değeri	€315.14k
Kazançlar(TTM)	-€8.41m
Gelir(TTM)	n/a

0.0x

P/S Oranı

0.0x

F/K Oranı

0NF0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0NF0 gelir tablosu (TTM)
Gelir	CA$0
Gelir Maliyeti	CA$0
Brüt Kâr	CA$0
Diğer Giderler	CA$12.46m
Kazançlar	-CA$12.46m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.20
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	-37.4%

0NF0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0NF0 Stoklara Genel Bakış

Ödüller

Risk Analizi

Mydecine Innovations Group Inc. Rakipler

XTRA:B8FK

€15.4m

DUSE:SBX

€27.9m

DB:93M1

€103.6m

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials